These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

577 related items for PubMed ID: 23903755

  • 1. TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma.
    Corcoran RB, Rothenberg SM, Hata AN, Faber AC, Piris A, Nazarian RM, Brown RD, Godfrey JT, Winokur D, Walsh J, Mino-Kenudson M, Maheswaran S, Settleman J, Wargo JA, Flaherty KT, Haber DA, Engelman JA.
    Sci Transl Med; 2013 Jul 31; 5(196):196ra98. PubMed ID: 23903755
    [Abstract] [Full Text] [Related]

  • 2. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.
    Atefi M, von Euw E, Attar N, Ng C, Chu C, Guo D, Nazarian R, Chmielowski B, Glaspy JA, Comin-Anduix B, Mischel PS, Lo RS, Ribas A.
    PLoS One; 2011 Jul 31; 6(12):e28973. PubMed ID: 22194965
    [Abstract] [Full Text] [Related]

  • 3. Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype.
    Ho AL, Musi E, Ambrosini G, Nair JS, Deraje Vasudeva S, de Stanchina E, Schwartz GK.
    PLoS One; 2012 Jul 31; 7(7):e40439. PubMed ID: 22808163
    [Abstract] [Full Text] [Related]

  • 4. Aberrant modulation of ribosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma.
    Gao MZ, Wang HB, Chen XL, Cao WT, Fu L, Li Y, Quan HT, Xie CY, Lou LG.
    Acta Pharmacol Sin; 2019 Feb 31; 40(2):268-278. PubMed ID: 29777202
    [Abstract] [Full Text] [Related]

  • 5. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
    Acquaviva J, Smith DL, Jimenez JP, Zhang C, Sequeira M, He S, Sang J, Bates RC, Proia DA.
    Mol Cancer Ther; 2014 Feb 31; 13(2):353-63. PubMed ID: 24398428
    [Abstract] [Full Text] [Related]

  • 6. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.
    Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, Burton EA, Wong B, Tsang G, West BL, Powell B, Shellooe R, Marimuthu A, Nguyen H, Zhang KY, Artis DR, Schlessinger J, Su F, Higgins B, Iyer R, D'Andrea K, Koehler A, Stumm M, Lin PS, Lee RJ, Grippo J, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, Chapman PB, Flaherty KT, Xu X, Nathanson KL, Nolop K.
    Nature; 2010 Sep 30; 467(7315):596-9. PubMed ID: 20823850
    [Abstract] [Full Text] [Related]

  • 7. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
    Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo RS.
    Nature; 2010 Dec 16; 468(7326):973-7. PubMed ID: 21107323
    [Abstract] [Full Text] [Related]

  • 8. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.
    Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC, Garraway LA.
    Nature; 2010 Dec 16; 468(7326):968-72. PubMed ID: 21107320
    [Abstract] [Full Text] [Related]

  • 9. The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression.
    Phadke MS, Sini P, Smalley KS.
    Mol Cancer Ther; 2015 Jun 16; 14(6):1354-64. PubMed ID: 25873592
    [Abstract] [Full Text] [Related]

  • 10. In Vivo ERK1/2 Reporter Predictively Models Response and Resistance to Combined BRAF and MEK Inhibitors in Melanoma.
    Sanchez IM, Purwin TJ, Chervoneva I, Erkes DA, Nguyen MQ, Davies MA, Nathanson KL, Kemper K, Peeper DS, Aplin AE.
    Mol Cancer Ther; 2019 Sep 16; 18(9):1637-1648. PubMed ID: 31270153
    [Abstract] [Full Text] [Related]

  • 11. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
    Jenkins MH, Croteau W, Mullins DW, Brinckerhoff CE.
    Matrix Biol; 2015 Oct 16; 48():66-77. PubMed ID: 25989506
    [Abstract] [Full Text] [Related]

  • 12. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.
    Joseph EW, Pratilas CA, Poulikakos PI, Tadi M, Wang W, Taylor BS, Halilovic E, Persaud Y, Xing F, Viale A, Tsai J, Chapman PB, Bollag G, Solit DB, Rosen N.
    Proc Natl Acad Sci U S A; 2010 Aug 17; 107(33):14903-8. PubMed ID: 20668238
    [Abstract] [Full Text] [Related]

  • 13. Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networks in BRAF and NRAS mutant melanoma.
    Fedorenko IV, Fang B, Munko AC, Gibney GT, Koomen JM, Smalley KS.
    Proteomics; 2015 Jan 17; 15(2-3):327-39. PubMed ID: 25339196
    [Abstract] [Full Text] [Related]

  • 14. eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies.
    Boussemart L, Malka-Mahieu H, Girault I, Allard D, Hemmingsson O, Tomasic G, Thomas M, Basmadjian C, Ribeiro N, Thuaud F, Mateus C, Routier E, Kamsu-Kom N, Agoussi S, Eggermont AM, Désaubry L, Robert C, Vagner S.
    Nature; 2014 Sep 04; 513(7516):105-9. PubMed ID: 25079330
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.
    Song H, Zhang J, Ning L, Zhang H, Chen D, Jiao X, Zhang K.
    Med Sci Monit; 2018 May 08; 24():3002-3010. PubMed ID: 29737325
    [Abstract] [Full Text] [Related]

  • 20. Drug discovery: How melanomas bypass new therapy.
    Solit D, Sawyers CL.
    Nature; 2010 Dec 16; 468(7326):902-3. PubMed ID: 21164474
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.